At Ignyta, we fight cancer – a formidable opponent that manifests as thousands of different molecularly defined diseases and takes away millions of lives globally, every year. In this fight, our vision is not just to shrink tumors but to eradicate residual disease – the source of cancer relapse and recurrence – in precisely defined patient populations by 2030. We will work tirelessly to achieve this vision by pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Our Rx efforts are focused on discovering, in-licensing or acquiring, then developing and commercializing, molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Our Dx efforts aim to pair these product candidates with biomarker-based companion diagnostics that are designed to precisely identify, at the molecular level, the patients who are most likely to benefit from the therapies we develop. We believe that only through this integrated Rx/Dx approach can we succeed in this fight.
Show more
Type
Subsidiary
Parent Company
Roche
HQ
San Diego, US
Founded
2011
Website
ignyta.com
Ignyta was founded in 2011 and is headquartered in San Diego, US
Report incorrect company information

Ignyta Office Locations

Ignyta has an office in San Diego
San Diego, US (HQ)
11095 Flintkote Ave
Show all (1)
Report incorrect company information

Ignyta Financials and Metrics

Summary Metrics

Founding Date

2011
Ignyta is a subsidiary of Roche

Ignyta Financials

Ignyta's revenue was reported to be $150 k in FY, 2014
Annual
USDY, 2013FY, 2014FY, 2015FY, 2016

Revenue

150 k

Revenue growth, %

(100%)

EBIT

(13.9 m)

Interest expense

203.8 k
Quarterly
USDQ1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

150 k

General and administrative expense

3.9 m3.9 m5.2 m5.5 m6.1 m5.6 m5.5 m

R&D expense

8.8 m10.4 m19.8 m20 m16.6 m34 m22.2 m

Operating expense total

12.7 m14.3 m25 m25.5 m22.8 m39.6 m27.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

51.8 m6.3 m46.4 m24.3 m

Inventories

1.7 m4.4 m

Current Assets

52.5 m71.3 m136.2 m111.9 m
Quarterly
USDQ1, 2014

Cash

52.6 m

Current Assets

78.9 m

Total Assets

102.1 m

Accounts Payable

1.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(14.2 m)(40 m)(92.5 m)(103.6 m)

Depreciation and Amortization

112.4 k527.7 k

Inventories

(800.7 k)

Accounts Payable

2.9 m95 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(79.4 k)(13.1 m)(14.6 m)(25.5 m)(26.7 m)(23.3 m)(40.2 m)

Accounts Payable

2 m797.9 k1.8 m1.8 m3.2 m8.8 m1.7 m2.1 m
Show all financial metrics
Report incorrect company information